Moderate to severe periodontitis
Conditions
Interventions
Test group 1. 25 patients 2. Patients take 500mg of test drug per day, once a day for 3 days
Control group 1. 25 patients. 2. Patients take 200mg of sitafloxacin hydrate (Gracevit) per day for 5
Sponsors
Niigata University Medical and Dental Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 20 years or older persons who obtained written informed consent. 2. Persons who have diagnosed as moderate to severe chronic or aggressive periodontitis. 3. Persons who have completed active periodontal treatment and received SPT. 4. Persons who have more than 15 teeth. 5. Persons who have more than 2 teeth with PD more than 5mm and BOP (+)
Exclusion criteria
Exclusion criteria: 1. Persons who received debridement in periodontal pockets for the past one month prior to this study. 2. Persons who received SRP with local anesthesia for the past three month prior to this study. 3. Persons who took antimicrobials (except external use) for the past three month prior to this study. 4. Persons who have the medical history of hypersensitivity to new quinolone or macrolide antimicrobials. 5. Persons who are pregnant or suspected to be pregnant. 6. Persons who have severe diabetes, heart diseases, or dysfunction of kidney or liver. 7. Persons who are judged to be unqualified for this study subjects by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of total bacteria and some periodontopathic bacteria in subgingival plaque | — |
Secondary
| Measure | Time frame |
|---|---|
| Probing pocket depth(PD) Bleeding on probing(BOP) Antibody levels in serum against periodontopathic bacteria Concentration of the drugs in gingival crevicular fluid | — |
Countries
Japan
Contacts
Public ContactTakako Nakajima
Niigata University Medical and dental hospital,
Outcome results
None listed